Han Kun represented BioRegen Biomedical (Changzhou) Co., Ltd. ("BioRegen") in its Series C equity financing
2013-06-07
BioRegen completed its Series C equity financing.
Han Kun represented BioRegen in its Series C equity financing, a company primarily engaged in the business of manufacturing 3rd grade 6864 medical sanitary materials and dressing, sales of self-manufactured products, development of biomedical products, medical apparatus and instruments and related products, and provision of relevant technical services.
Han Kun primarily assisted in the legal due diligence investigation, preparation of various transaction documents and participated in the negotiation process.
The leading lawyers involved in this deal are Charles Li, Yijun Chao, Yang Chen, Loretta Li and Hong Li.